Singapore-based healthtech startup, Neuroglee Therapeutics has secured $2.3m in pre-seed funding.
Eisai Co. Ltd, a global pharmaceutical company headquartered in Tokyo, Japan participated in the round along with Kuldeep Singh Rajput, Founder & CEO of Biofourmis.
The health-tech startup seeks to use the funding to advance the product pipeline for NG-001, their product which is a prescription software intended for treatment of MCI and patients with early stage Alzheimer’s Disease.
Aniket Singh Rajput, Founder and CEO of Neuroglee, said – “Neurodegenerative diseases is a severely underserved market, yet also one that is constantly growing as our population continues to age. Through the power of software, we are able to combine our expertise in cognitive neuroscience, behaviour modification and digital biomarkers into a digital form of treatment that augments conventional medication and bridges the gap between patient and clinician. We are excited to work with Eisai and leading experts in scaling digital health solutions to facilitate a better quality of life for patients and caregivers, as well as to pave the way for faster development of effective cures.”
Neuroglee Therapeutics discovers, develops, and commercializes software as medical treatment for patients with neurodegenerative diseases. By combining cognitive rehabilitation strategies and machine learning approaches, its digital therapeutic and monitoring tools help patients, families and clinicians to preserve cognition and independence.
–AK
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.